Citius Pharmaceuticals Inc Stock Price, News & Analysis

Citius Pharmaceuticals, Inc. (CTXR) announced the appointment of Kelly Creighton, PhD, as Executive Vice President of Chemistry, Manufacturing and Controls. Dr. Creighton brings nearly two decades of pharmaceutical industry expertise, with over 50 investigational new drug submissions and 20 approved applications. He will oversee global regulatory and manufacturing strategies for Citius's five pipeline programs, as the company prepares for commercial success with two late Phase 3 trials nearing completion. Management expresses confidence in his ability to drive the company’s clinical development and regulatory pathways forward.

Citius Pharmaceuticals (Nasdaq: CTXR) announced a KOL webinar on November 11, 2021, at 11:30 AM ET addressing the salvage of central venous catheters in patients with CLABSI. Leading experts Issam Raad from MD Anderson and Mark Rupp from the University of Nebraska will discuss the unmet medical needs and the impact of COVID-19 on infection rates. Citius's Chief Medical Officer, Myron Czuczman, will provide updates on Mino-Lok®, their antibiotic treatment for catheter-related infections, currently in a Phase 3 clinical trial. Pre-registration is required for participation.

Citius Pharmaceuticals (Nasdaq: CTXR) will host a webcast on October 20, 2021, at 8:30 a.m. ET, to discuss its acquisition of I/ONTAK (E7777), an enhanced formulation of the immunotoxin ONTAK, previously FDA-approved for cutaneous T-cell lymphoma (CTCL). CEO Myron Holubiak and other executives will outline the company's strategy and the potential of I/ONTAK, which has received regulatory approval in Japan and orphan drug designation from the FDA. A pivotal study on I/ONTAK is underway, with results expected in mid-2022.

Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in two investor conferences in October 2021. The first event is the Benzinga Rising Stars Conference on October 7, 2021, where Executive Chairman Leonard Mazur will present at 9:05 a.m. ET. The second is the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021, with Mazur presenting at 8:55 a.m. ET. Citius is focused on critical care products in oncology, including late-stage assets like Mino-Lok^® and I/ONTAK (E7777).

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that Leonard Mazur, Executive Chairman, and his wife, Helena, were honored by Temple University, which renamed its main building for the College of Liberal Arts to Leonard and Helena Mazur Hall. This honor recognizes their significant contributions to the university and commitment to enhancing student opportunities. The event occurred on September 30, 2021, and underscores the Mazurs' role in supporting higher education and career development for students. Citius continues to focus on critical care products, including two late-stage therapies.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will join Benzinga's All Access Show for a 20-minute interview on September 17, 2021, at 10:10 am ET. Chairman Leonard Mazur will discuss advancements in the company's late-stage clinical pipeline, focusing on I/ONTAK (E7777), a novel oncology asset with potential for near-term revenue and a robust path toward commercial success. Citius is noted for its late-stage candidates, including Mino-Lok®, which is in a Phase 3 trial, and I/ONTAK, having completed enrollment in its pivotal Phase 3 trial.

Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The company will provide a presentation video available on demand starting at 7:00 am ET on September 13th. Key discussions will include the company's expanded pipeline and upcoming catalysts, featuring insights from CEO Myron Holubiak and CMO Myron Czuczman. The archived webcast will be up for 90 days post-event. Citius focuses on critical care products in oncology, anti-infectives, and stem cell therapies.

Citius Pharmaceuticals, Inc. (CTXR) announced a definitive agreement to acquire Dr. Reddy's Laboratories' exclusive license for E7777, an advanced oncology immunotherapy for treating Cutaneous T-cell Lymphoma (CTCL). The acquisition involves a $40 million upfront payment, additional milestones totaling up to $110 million, and royalty payments on net sales. E7777, a reformulated version of ONTAK, is nearing FDA approval with a Biologics License Application expected by late 2022. Citius aims to enhance its pipeline and target approximately 30% of the CTCL patient population, estimated at 30,000 to 40,000 in the U.S.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) reported its financial results for Q3 2021, showing a net loss of $5.8 million and cash equivalents of $115.7 million. Key highlights include a positive recommendation from the Data Monitoring Committee for the Mino-Lok® trial and advances in stem cell therapy development. The company also raised $127.6 million in financing during H1 2021, with an increase in authorized shares to support growth. However, recruiting for the Mino-Lok® trial may slow due to COVID-19 disruptions.